RRA
KNSA icon

Round Rock Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Round Rock Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$462K Hold
7,226
– – 0.06% 223
2026
Q1 		$348K Buy
7,226
+171
+2% +$7.58K 0.05% 243
2025
Q4 		$291K Buy
7,055
+1,899
+37% +$76.2K 0.04% 271
2025
Q3 		$201K Buy
+5,156
New +$168K 0.03% 316

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Round Rock Advisors's KNSA Position: Q2 2026 in Review

Round Rock Advisors held its Kiniksa Pharmaceuticals (KNSA) position steady in Q2 2026 at 7,226 shares worth $462K. The position accounts for 0.06% of the portfolio, ranked #223.

Round Rock Advisors first reported a position in KNSA in Q3 2025 and has held it in 4 quarters since. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Round Rock Advisors held 7,226 shares of Kiniksa Pharmaceuticals worth $462K as of Q2 2026.
  • Round Rock Advisors left its Kiniksa Pharmaceuticals share count unchanged in Q2 2026.
  • Kiniksa Pharmaceuticals made up 0.06% of Round Rock Advisors's portfolio in Q2 2026, its #223 holding.
  • Round Rock Advisors first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Round Rock Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.